康悦达过敏性鼻炎获批快于预期,鼻科市场放量在即2025 年2 月7 日,公司宣布其自主研发的1 类新药康悦达(司普奇拜单抗)针对季节性过敏性鼻炎(SAR)适应症获NMPA 批准上市。IL-4R 单抗在治疗2 型炎症通路介导的自免疾病领域均具有较好的临床疗效,公司IL-4R 单抗已有3 个适应症获批上市,其中成人中重度特应性皮炎与慢性鼻窦炎伴鼻息肉适应症分别于2024 年9 月10 日与2024 年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.